Navigation Links
InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
Date:7/23/2008

SAN FRANCISCO, July 23 /PRNewswire/ -- InCode BioPharmaceutics, Inc., an emerging biopharmaceutical company, today announced preclinical test results demonstrating the utility of their lead drug candidate rC3-1 for the treatment of the rare chronic blood disorder paroxysmal nocturnal hemoglobinuria (PNH). The complete results will be presented at the XXII International Complement Workshop in Basel, Switzerland, September 28, 2008.

The only treatment currently available for PNH patients is an anti-C5 antibody Soliris(TM) (eculizumab) sold by Alexion Pharmaceuticals, Inc.

rC3-1 promotes the enzymatic partial depletion of C3, the hub of the complement cascade. Complement protein C3 is the master regulator of complement protein C5 that mediates cell damage in PNH patients. The reduction of C3 has been shown to reduce PNH cell destruction.

PNH is a rare debilitating and life-threading disease. PNH is an acquired genetic blood disorder in which patients' red blood cells are destroyed by complement, a component of the body's immune system. PNH patients have a sub-population of red blood cells (PNH cells) that are susceptible to immune complement-mediated destruction. In this study, PNH cells from patients remained intact in blood serum treated with rC3-1 when compared to non-treated serums.

"rC3-1 appears to be a promising new treatment alternative with several benefits over the existing treatment," Commented Bill St. John CEO of InCode. "The unique action of rC3-1, offers patients the potential for more convenient self-administered dosing and physicians' a more cost effective and flexible treatment option."

InCode is planning PNH clinical trials testing rC3-1. These trials will provide a foundation for series of subsequent clinical trials addressing macular degeneration, asthma and other autoimmune and inflammatory disease indications.

InCode BioParmaceutics, Inc. is an emerging biotechnology company that is developing a ne
'/>"/>

SOURCE InCode BioPharmaceutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... HIV Vaccine--PHILADELPHIA, May 17 A research team may ... invention of an effective HIV vaccine, by using an ... developers. By using gene transfer technology that produces molecules ... by a virus closely related to HIV -- the ...
... Findings Confirm Glycerin Accelerates the Healing Process , ... Today , a leading expert ... from a study demonstrating that glycerin helps to speed ... resulting in less bruising and skin discoloration.In a double-blinded, ...
Cached Medicine Technology:Novel Vaccine Approach Offers Hope in Fight Against HIV 2Novel Vaccine Approach Offers Hope in Fight Against HIV 3Glycerin Proven to Improve Bruising and Swelling Caused By Trauma to Skin 2
(Date:7/9/2014)... policing injection drug users in Russia might contribute ... A study, conducted by researchers from Boston University ... with St. Petersburg Pavlov State University, sought to ... health outcomes of a cohort of HIV-positive people ... who were arrested by police were more likely ...
(Date:7/9/2014)... in French . ... old teens, including brain structure and function, personality, life experiences ... go on to develop binge drinking within the next two ... variables such as life events and a family history of ... Whether or not the child had had a single drink ...
(Date:7/9/2014)... world have been linked to an emerging fungal ... National Institute for Mathematical and Biological Synthesis (NIMBioS) ... , In a series of mathematical models, ... of internal organs in frogs, could cause extinction ... are exposed to the virus every few years, ...
(Date:7/9/2014)... Infectious Diseases (NIAID), part of the National Institutes ... of CRS3123, an investigational oral antibiotic intended to ... ) infection. CRS3123 (previously known as REP3123) is ... while sparing normal intestinal bacteria. , The Phase ... men and women ages 18 to 45 in ...
(Date:7/9/2014)... labels handed out by pharmacists may be misread ... according to new research by the University of ... Blind)., The study, published recently in the ... prescription medications dispensed by pharmacies do not consistently ... simply following recommended guidelines for font size, use ...
Breaking Medicine News(10 mins):Health News:BU researchers relate arrests with HIV risk environment 2Health News:What drives a child to abuse alcohol? 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... ... free NeedyMeds iPhone app . , ... (Vocus) August 21, 2009 -- NeedyMeds, the premier source of information on programs that help ... its drug discount card. Simply by showing the pharmacist an image on their iPhones, people can ...
... , , , LOS ... Inc., announced the launch of Energy-X, a new lip balm that delivers ... or artificial sweeteners. With zero calories, Energy-X provides the energy boost consumers ... , "Energy-X is applied directly on the lips and ...
... all know that influenza vaccination helps prevent disease, but ... prevent another public health problem: inappropriate antibiotic use. The ... 1, 2009 issue of Clinical Infectious Disease , ... the Canadian province of Ontario introduced a universal immunization ...
... Increase is small but worth noting, expert says, as ... -- Smokeless tobacco increases the risk of fatal heart ... of 11 studies conducted in North America and Sweden. ... of smokeless tobacco products has increased in Europe and ...
... to list the negative stereotypes attributed to the elderly: ... What,s unsettling is that those stereotypes can be ... Research conducted by the University of Alberta,s Sheree ... stereotypes exist in some children at that age, which ...
... , WASHINGTON, Aug. 20 Congressman Chaka ... national "March for Healthcare" in Washington on September 13 to mobilize ... announced today. , , The Philadelphia Congressman, ... on colleagues in Congress to endorse the proposal for a march, ...
Cached Medicine News:Health News:iPhone App That Saves Money on Prescription Medicines 2Health News:Energy-X Lip Balm Delivers Wake-Up Call to Consumers 2Health News:Visits to Nana's may keep toddlers from developing negative age stereotypes 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: